Vertex Pharmaceuticals vs Viatris
VRTX and VTRS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How VRTX and VTRS compare
Vertex Pharmaceuticals is the larger company, worth 5.7 times as much as Viatris ($137B against $23.9B).
Vertex Pharmaceuticals grew revenue faster over the last twelve months (10.2% versus 4.3% for Viatris).
Viatris pays a dividend yielding 2.3%; Vertex Pharmaceuticals does not pay one.
Vertex Pharmaceuticals scores higher on the StockData Score (15 against 6 for Viatris), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | VRTX | VTRS |
|---|---|---|
| Size and price | ||
| Market cap | $137B | $23.9B |
| Share price | $538.60 | $20.82 |
| Change, 1 year | 24.0% | 89.1% |
| Change, 5 years | 195% | 59.2% |
| Beta (5Y) | 0.52 | 0.86 |
| Employees | 600K | 30K |
| StockData Score | ||
| Total score | 15 (better) | 6 |
| Valuation score | 0 | 2 (better) |
| Growth score | 3 (better) | 1 |
| Performance score | 6 (better) | 0 |
| Health score | 6 (better) | 1 |
| Dividend score | 0 | 2 (better) |
| Valuation | ||
| P/E | 31.4× | – |
| P/S | 10.8× | 1.6× (better) |
| P/B | 6.7× | – |
| EV/EBITDA | 25.7× | 12.6× (better) |
| P/FCF | 36.0× | 11.3× (better) |
| PEG | 5.12 | – |
| FCF yield | 2.8% | 8.8% (better) |
| Fair value | $426.36 | $23.22 |
| Margin of safety | −26.3% | 10.4% (better) |
| Growth | ||
| Revenue growth (TTM) | 10.2% (better) | 4.3% |
| Revenue growth, 5Y average | 14.1% (better) | 3.7% |
| Net income growth (TTM) | 21.1% | – |
| EPS growth (TTM) | 22.4% | – |
| EPS growth, 5Y average | 8.3% | – |
| Profitability | ||
| Gross margin | 86.0% (better) | 35.3% |
| Operating margin | 38.0% (better) | −0.03% |
| Net margin | 35.0% | – |
| FCF margin | 30.2% (better) | 14.3% |
| Return on equity | 23.5% | – |
| Return on invested capital | 34.4% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Net debt / EBITDA | – | 4.10 |
| Interest coverage | – | −0.0× |
| Current ratio | 3.19 (better) | 1.55 |
| Altman Z-score | 13.63 (better) | 1.21 |
| Piotroski F-score | 7 | – |
| Dividends and buybacks | ||
| Dividend yield | – | 2.3% |
| Years of dividend growth | – | 0 |
| Buyback yield | 1.5% | 1.6% (better) |
| Shareholder yield | 1.5% | 3.9% (better) |
| Ownership | ||
| Held by institutions | 95.6% | 91.5% |
| Held by insiders | 0.22% | 0.36% |
| Insider net buying, 12 months | −$131M | −$1.1M (better) |
| Superinvestors holding | 1 | 3 (better) |
| Short interest, % of float | 1.9% | 3.1% |
Go deeper
- VRTX stock overview
- VRTX income statement
- VRTX valuation and score
- VTRS stock overview
- VTRS income statement
- VTRS valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.